Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension

Gut

Volumn 60, Issue 8, 2011, Pages 1133-1138

  La Mura, Vincenzo ^a,b   Reverter, Juan Carlos ^a   Flores Arroyo, Alexandra ^a,b   Raffa, Sebastián ^a,b   Reverter, Enric ^a,b   Seijo, Susana ^a,b   Abraldes, Juan G ^a,b   Bosch, Jaime ^a,b   García Pagán, Juan Carlos ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISO PROSTAGLANDIN F2 ALPHA; ISOPROSTANE DERIVATIVE; PADGEM PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL TONE; CARDIOPULMONARY PRESSURE; CLINICAL ARTICLE; DEATH; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEMODYNAMICS; HEPATIC VEIN; HEPATIC VENOUS PRESSURE GRADIENT; HUMAN; LIVER BLOOD VESSEL; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PERIPHERAL VEIN; PORTAL HYPERTENSION; PREDICTION; PRESSURE; PRESSURE GRADIENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; YOUDEN INDEX;

BIOLOGICAL MARKERS; DINOPROST; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; P-SELECTIN; PROGNOSIS; RETROSPECTIVE STUDIES; VASODILATION; VON WILLEBRAND FACTOR;

EID: 79960322140     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.235689     Document Type: Article

References (35)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32(1 Suppl):141-56.
2. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008;47:1248-56. (Pubitemid 351547911)
3. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-34. (Pubitemid 46529052)
4. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006;44:44-52. (Pubitemid 44055834)
5. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008;117:1449-59. (Pubitemid 351501497)
6. Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009;7:1759-66.
7. Lavi S, Yang EH, Prasad A, et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 2008;51:127-33. (Pubitemid 350307114)
8. van Mourik JA, Boertjes R, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999;94:179-85. (Pubitemid 29300147)
9. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95. (Pubitemid 46594773)
10. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002;37:280-7. (Pubitemid 34833094)
11. Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996;23:1377-83. (Pubitemid 26181219)
12. Albornoz L, Alvarez D, Otaso JC, et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999;30:451-5. (Pubitemid 29113234)
13. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103:491-5.
14. Chironi G, Dosquet C, Del-Pino M, et al. Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men. Am J Hypertens 2006;19:1025-31. (Pubitemid 44488665)
15. Reiner AP, Carlson CS, Thyagarajan B, et al. Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol 2008;28:1549-55.
16. Vardareli E, Saricam T, Demirustu C, et al. Soluble P selectin levels in chronic liver disease: relationship to disease severity. Hepatogastroenterology 2007;54:466-9. (Pubitemid 46724708)
17. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001;280:L1067-82.
18. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004;38:105-22. (Pubitemid 38181167)
19. Cracowski JL, Devillier P, Durand T, et al. Vascular biology of the isoprostanes. J Vasc Res 2001;38:93-103. (Pubitemid 32337211)
20. Pratico D, Rossi E, Merli M, et al. Portal levels of the isoprostane F2 alpha-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients. J Investig Med 1998;46:430-4. (Pubitemid 128455013)
21. Silveira AM, Yamamoto T, Adamson L, et al. Application of an enzyme-linked immunosorbent assay (ELISA) to von Willebrand factor (vWF) and its derivatives. Thromb Res 1986;43:91-102. (Pubitemid 16016282)
22. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77:1081-5. (Pubitemid 27311973)
23. Krier JD, Rodriguez-Porcel M, Best PJ, et al. Vascular responses in vivo to 8-epi PGF (2alpha) in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol 2002;283:R303-8.
24. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
25. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's index 2. Stat Med 1996;15:969-86.
26. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
27. von Kanel R, Dimsdale JE, Adler KA, et al. Effects of nonspecific beta-adrenergic stimulation and blockade on blood coagulation in hypertension. J Appl Physiol 2003;94:1455-9. (Pubitemid 36348822)
28. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039-46. (Pubitemid 46489567)
29. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anticoagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105-11.
30. Hollestelle MJ, Geertzen HG, Straatsburg IH, et al. Factor VIII expression in liver disease. Thromb Haemost 2004;91:267-75. (Pubitemid 38240171)
31. Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-47.
32. Zecchini R, Ferrari A, Bernabucci V, et al. Anticoagulant therapy is safe and effective in preventing portal vein thrombosis (PVT) in advanced cirrhotic patients: a prospective randomized controlled study. J Hepatol 2010;52:460A.
33. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61. (Pubitemid 44049138)
34. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-5.
35. Patel KN, Soubra SH, Bellera RV, et al. Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia. Arterioscler Thromb Vasc Biol 2008;28:2225-30.